このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Shineco マネジメント

マネジメント基準チェック /04

主要情報

Jennifer Zhan

最高経営責任者

US$70.0k

報酬総額

CEO給与比率	85.7%
CEO在任期間	2.9yrs
CEOの所有権	0.07%
経営陣の平均在職期間	2.3yrs
取締役会の平均在任期間	2.9yrs

経営陣の近況

Recent updates

Shineco CEO steps down, new CEO appointed

May 07

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

May 04

CEO報酬分析

Shineco の収益と比較して、Jennifer Zhan の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	n/a	n/a	-US$14m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	US$70k	US$60k	-US$10m
Mar 31 2023	n/a	n/a	US$2m
Dec 31 2022	n/a	n/a	US$2m
Sep 30 2022	n/a	n/a	US$2m
Jun 30 2022	US$70k	US$60k	-US$8m

CEO（最高経営責任者

Jennifer Zhan (35 yo)

2.9yrs

在職期間

US$70,000

報酬

Ms. Jennifer Zhan has been Chief Executive Officer of Shineco, Inc. since July 15, 2021 and has been its Executive Director since July 14, 2021. She was a founding partner of Tian ‘Ang capital Beijing Inve...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jennifer Zhan	CEO & Executive Director	2.9yrs	US$70.00k	0.067% $ 16.3k
Sai Wang	CFO & Director	9.3yrs	US$106.00k	0.13% $ 31.6k
Xiqiao Liu	COO & Executive Director	2.3yrs	US$10.00k	0.067% $ 16.3k
Wang Xiaohui	Executive President	less than a year	データなし	データなし
Fenming Liu	Chief Scientist	no data	データなし	データなし
Qiyin Sun	Chief Medical Consultant	2.3yrs	データなし	データなし
Chi Keung Yan	Chief Strategy Officer	less than a year	データなし	データなし

2.3yrs

平均在職期間

44yo

平均年齢

取締役

名称	ポジション	在職期間	報酬	所有権
Jennifer Zhan	CEO & Executive Director	2.9yrs	US$70.00k	0.067% $ 16.3k
Sai Wang	CFO & Director	8yrs	US$106.00k	0.13% $ 31.6k
Xiqiao Liu	COO & Executive Director	2.3yrs	US$10.00k	0.067% $ 16.3k
Aamir Quraishi	Independent Director	1.8yrs	US$10.00k	データなし
Hu Li	Independent Director	2.8yrs	US$10.00k	データなし
Jin Liu	Independent Director	3.8yrs	US$10.00k	データなし
Mike Zhao	Independent Chairman of the Board	2.9yrs	US$10.00k	データなし

2.9yrs

平均在職期間

49yo

Shineco マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

Shineco, Inc., Annual General Meeting, Jun 28, 2023

High number of new and inexperienced directors

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Shineco, Inc. Resigns Yanzeng as Member of the Board of Directors

Recent updates

Shineco Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Requirement Under Nasdaq Listing Rule 5550(a)(2)

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New major risk - Financial position

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

New major risk - Share price stability

New major risk - Financial position

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.60 loss in FY 2022)

Shineco Not Regains Compliance with the Nasdaq's Minimum Bid Price Requirement

Shineco, Inc.'S Subsidiary, Changzhou Biowin Pharmaceutical Co., Ltd., Receives Marketing Approval from China's Regulatory Body for Its Cardiac 5 Minute Test

New major risk - Market cap size

Shineco, Inc., Annual General Meeting, Jun 28, 2023

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.30 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2022)

Shineco, Inc. (NasdaqCM:SISI) signed a letter of intent to acquire 80% stake in Dream Partner Limited for $40 million.

First quarter 2023 earnings released: US$0.17 loss per share (vs US$1.34 loss in 1Q 2022)

High number of new and inexperienced directors

Shineco Receives Deficiency Letter from Nasdaq

Full year 2022 earnings released: US$2.60 loss per share (vs US$4.73 loss in FY 2021)

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Shineco, Inc. Resigns Yanzeng as Member of the Board of Directors

High number of new and inexperienced directors

Shineco, Inc. Announces Management Changes

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shineco, Inc. Appoints Qiyin Sun as Chief Medical Consultant

High number of new directors

Shineco, Inc. (NasdaqCM:SISI) entered into an agreement to acquire 51% stake in Xiang Peng You Kang (Beijing) Technology Co., Ltd.

Independent Director Harry Edelson has left the company

High number of new directors

Third quarter 2021 earnings released: US$2.36 loss per share (vs US$1.26 loss in 3Q 2020)

Shineco CEO steps down, new CEO appointed

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding terms of proposal to acquire a 51% stake in Mayah Biological Holdings Limited.

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

Shineco, Inc. announced delayed 10-Q filing

New 90-day high: US$4.15

New 90-day high: US$3.82

New 90-day high: US$3.31

First quarter 2021 earnings released: US$0.35 loss per share

Full year earnings released - US$2.25 loss per share

New 90-day low - US$2.71

Shineco, Inc. Announces Management Changes

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding Letter of Intent to acquire 73.7% stake in Changzhou Biowin Pharmaceutical Co., Ltd from Beijing Kanghuayuan Technology Development Co., Ltd and Changzhou Kelinbo Venture Capital Partnership (limited partnership) for $25 million.

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04